Momentus Inc. 2026 Special Meeting Summary Company Overview - **Company**: Momentus Inc. (NasdaqCM: MNTS) - **Event**: 2026 Special Meeting of Stockholders - **Date**: February 06, 2026 Key Proposals Discussed 1. **Issuance of Class A Common Stock for Convertible Notes and Warrants** - Proposal to approve the issuance of Class A Common Stock in connection with the exercise of certain existing convertible notes and warrants exceeding 19.99% of outstanding shares, in accordance with Nasdaq Listing Rule 5635(d) [10] - Board recommends a vote for this proposal [10] 2. **Equity Line of Credit and Pre-Funded Warrants** - Proposal to approve the issuance of Class A Common Stock to an investor related to the company's Equity Line of Credit and the exercise of certain Pre-Funded Warrants, also exceeding 19.99% of outstanding shares [11] - Board recommends a vote for this proposal [11] 3. **October 2025 Inducement Warrants** - Proposal to approve the issuance of Class A Common Stock to holders of certain existing October 2025 inducement warrants, exceeding 19.99% of outstanding shares [12] - Board recommends a vote for this proposal [12] 4. **Increase in Authorized Shares** - Proposal to amend the company's certificate of incorporation to increase the number of authorized shares of Class A common stock from 250 million to 260 million [12] - Board recommends a vote for this proposal [12] 5. **December 2025 Inducement Warrants** - Proposal to approve the issuance of Class A Common Stock to holders of certain existing December 2025 inducement warrants, exceeding 19.99% of outstanding shares [13] - Board recommends a vote for this proposal [13] 6. **Postponement or Adjournment of Meeting** - Proposal to allow for the postponement or adjournment of the meeting if necessary to solicit further votes on the proposals [14] - Board recommends a vote for this proposal [14] 7. **January 2026 Warrants** - Proposal to approve the issuance of Class A Common Stock to holders of certain existing January 2026 warrants, exceeding 19.99% of outstanding shares [15] - Board recommends a vote for this proposal [15] Voting Results - Preliminary results indicated that the following proposals were approved: - Convertible note and warrants proposal - Equity line of credit proposal - October 2025 inducement warrant proposal - December 2025 inducement warrant proposal - Adjournment proposal - January 2026 warrant proposal - The share increase proposal was not approved [17] Additional Information - A quorum was declared present with more than one-third of Class A Common Stock represented [9] - The meeting was conducted virtually, allowing stockholders to vote online [4] - Final vote results will be reported to the SEC in a Form 8-K within four business days [17]

Summary of Veeco Instruments Inc. Special Meeting Company Overview - **Company**: Veeco Instruments Inc. (NasdaqGS:VECO) - **Meeting Date**: February 06, 2026 - **Purpose**: Special meeting of stockholders to discuss and vote on key proposals Key Proposals Discussed 1. **Merger Proposal** - Proposal for the adoption of the Agreement and Plan of Merger dated September 30, 2025, involving Veeco Instruments, Axcelis Technologies, Inc., and Victory Merger Sub, Inc. - The merger will result in Victory Merger Sub, Inc. merging with Veeco, with Veeco becoming a wholly owned subsidiary of Axcelis Technologies, Inc. - Approval requires a majority vote from the holders of the issued and outstanding shares of common stock entitled to vote at the meeting [6][7] 2. **Merger Compensation Proposal** - Non-binding advisory vote on the compensation for the company's named executive officers related to the merger transactions. - Requires a majority of the total votes cast at the meeting for approval [7] 3. **Adjournment Proposal** - Proposal to approve the adjournment of the meeting if necessary to solicit additional proxies or ensure timely provision of any amendments to the proxy statement. - Requires a majority of the total votes cast at the meeting for approval [8] Voting Process - Stockholders had the opportunity to vote virtually or in person. - Voting was conducted via proxy, written ballot, and electronic ballot. - Each share of common stock was entitled to one vote, with a total of 60,297,087 shares outstanding as of the record date [4][8] Meeting Outcomes - The merger proposal, merger compensation proposal, and adjournment proposal were all approved based on preliminary voting results. - Since the merger proposal was approved, the adjournment proposal was not acted upon [11] Additional Information - The results of the voting will be published in a current report on Form 8-K filed with the Securities and Exchange Commission [11] - The meeting concluded with thanks to the stockholders for their attendance and interest in Veeco Instruments, Inc. [11][12]

Bayer (OTCPK:BAYR.Y) Update / briefing February 06, 2026 09:00 AM ET Company ParticipantsAlek Ebbeling - Associate Director of Pharmaceuticals Equity ResearchAlexander Seidler - Head of Investor RelationsAshkan Shoamanesh - Professor of Neurology, and Director of the Stroke ProgramChristoph Koenen - Global Head of Clinical Development and OperationsJan Foss - Global Head of AsundexianRajesh Kumar - Head of European Life Sciences and Healthcare ResearchConference Call ParticipantsCharles Pitman-King - Direct ...

Advanced Info Service Public Company (OTCPK:AVIF.Y) 2026 Investor Day February 06, 2026 01:00 AM ET Company ParticipantsPhupa Akavipat - Chief Enterprise Business OfficerPratthana Leelapanang - CEOSomruetai Tantakitti - Head of Investor RelationsTee Seeumpornroj - CFONone - Video NarratorSomruetai TantakittiGood afternoon everyone, and welcome to our Investor Day for 2026, the next growth chapter. Today, let me remind you that participants on Zoom, if you want to listen in English, you may choose English ro ...

ZenaTech (NasdaqCM:ZENA) Conference February 05, 2026 04:00 PM ET Company ParticipantsJames Sherman - CFOLinda Montgomery - VP of Corporate DevelopmentConference Call ParticipantsPat McCann - Equity Research AnalystPat McCannHello, everyone. My name is Pat McCann, a Research Analyst here with Noble Capital Markets. Thanks for joining us today. Today, we have Jim Sherman and Linda Montgomery with ZenaTech. Before I hand the floor over to them, I just wanna give a quick reminder that if you have any questions ...

Denali Therapeutics (NasdaqGS:DNLI) Update / briefing February 05, 2026 03:30 PM ET Company ParticipantsAnanda Ghosh - Managing DirectorJoseph Lewcock - Chief Scientific OfficerPeter Chin - Acting Chief Medical Officer and Head of DevelopmentRyan Watts - CEOConference Call ParticipantsAndrew Tsai - Senior Research AnalystCharles Moore - AnalystDavid Hoang - AnalystJay Olson - Senior Research AnalystJoseph Thome - AnalystMayank Mamtani - AnalystMichael DiFiore - AnalystMichael Yee - AnalystMyles Minter - Ana ...

Summary of IN8bio Conference Call - February 05, 2026 Company Overview - **Company**: IN8bio (NasdaqGM:INAB) - **Focus**: Development of cellular therapies using gamma delta T cells - **Key Personnel**: William Ho (CEO), Dr. Larry Lamb (Chief Scientific Officer) [1][2] Core Programs and Pipeline - **Ongoing Programs**: - **INB-100**: Allogeneic cell therapy for leukemia patients undergoing transplantation, currently enrolling an expansion cohort with updated phase one data expected by year-end [3] - **INB-619**: T cell engager platform targeting CD19 for both oncology and autoimmune diseases [3] - **INB-200 and INB-400**: Genetically modified gamma-delta T cell programs targeting solid tumors, particularly glioblastoma [3][4] Glioblastoma Treatment Insights - **Mechanism of Action**: Targets the DNA damage response (DDR) pathway, which is fundamental to all cells, making it potentially applicable to various solid tumors [33] - **Clinical Trial Results**: - Patients treated with INB-200 and INB-400 showed a median progression-free survival (PFS) of 13 months, compared to 6.6 months in the control group [14] - Overall survival (OS) for treated patients reached 17.2 months, with some patients remaining progression-free for over 4 years [15][47] - No major toxicity signals or adverse events reported [11] T Cell Engager Platform - **INB-619**: A unique CD19 targeting T cell engager designed to minimize cytokine release syndrome (CRS) while effectively depleting B cells [22][27] - **Comparative Efficacy**: INB-619 demonstrated comparable or superior potency to existing B-cell depleters like Amgen's blinatumomab and Roche's mosunitumab, with a significantly wider therapeutic window [26][27] Financial and Operational Updates - **Recent Financing**: Raised $20.1 million led by Coastlands Capital, with participation from Franklin Templeton and other investors, providing runway through 2027 [28][50] - **Upcoming Milestones**: - Public peer-reviewed publication of glioblastoma data - FDA guidance on regulatory path for glioblastoma program - Mouse data for INB-619 expected by late summer [53] Additional Insights - **Market Positioning**: IN8bio has chosen not to pursue autoimmune diseases with cell therapies, focusing instead on oncology due to concerns about the safety and efficacy of existing treatments in that area [20] - **Histopathology Findings**: Analysis of treated patients showed significant infiltration of gamma-delta T cells, indicating effective targeting of tumors [19] Conclusion - IN8bio is making significant strides in the development of innovative therapies for glioblastoma and leukemia, with promising clinical results and a solid financial foundation to support ongoing research and development efforts [29]

Summary of Volatus Aerospace Conference Call Company Overview - **Company Name**: Volatus Aerospace - **Stock Symbols**: OTCQX: TAKOF, TSXV: FLT - **Business Model**: Dual-use aerial intelligence and logistics platform operating in regulated environments such as energy, infrastructure, and public safety [2][3] Core Industry Insights - **Market Shift**: There is a clear shift in global priorities towards sovereignty and operational resilience, with a preference for dual-use capabilities that are proven in commercial environments [3][4] - **Customer Preferences**: Customers are moving away from point solutions to long-term operating partners that can sustain capabilities over time [4][5] - **Regulatory Environment**: Regulatory changes are evolving, with Canada allowing larger drones to operate beyond visual line of sight, creating significant opportunities [21][22] Financial Performance - **Revenue Growth**: Revenue grew by 60% in Q3 2025 to CAD 10.6 million, with gross margins between 32% and 34% [13] - **Profitability Improvement**: EBITDA drain reduced from approximately CAD 3 million to less than CAD 500,000 per quarter [14] - **Cash Position**: The company had CAD 40 million in cash at the end of 2025, with CAD 20 million in long-term contracts and a CAD 10 million backlog [15] Market Positioning - **Valuation Discrepancy**: Volatus is trading at less than 13 times trailing 12 months' revenue, while comparable companies are trading at over 90 times, indicating a significant market opportunity [15][16] - **Insider Holdings**: Approximately 21% insider holdings, with no insider selling, indicating confidence in the company's long-term prospects [16][17] Strategic Growth Areas - **Core Markets**: Focus on energy, critical infrastructure, public sector, and safety missions, with sovereign and defense as major growth areas [7][8] - **Expansion Plans**: Establishing a U.S. base in Tulsa, Oklahoma, to expand pipeline operations, with a long-term technology roadmap to introduce drones [12][19] Competitive Advantages - **Regulatory Credibility**: Operating in regulated environments creates barriers to entry that take years to build [9] - **Operational Efficiency**: Centralized operations allow for scaling without a linear increase in personnel or infrastructure [7][9] - **Platform Agnostic**: Flexibility to operate across multiple aircraft systems reduces dependency on any single platform [9] Future Outlook - **Defense Demand**: Anticipated growth in defense-related revenue, with strong demand for autonomous technologies expected to continue for the next three to five years [27][28] - **Manufacturing Focus**: Increased emphasis on domestic manufacturing to support defense needs, with a new facility in Mirabel, Quebec [19][20] Conclusion - Volatus Aerospace is positioned for significant growth in the dual-use aerial intelligence market, with strong financial performance, a solid operational model, and a strategic focus on expanding its capabilities in both commercial and defense sectors. The company is well-aligned with current market demands and regulatory trends, presenting a compelling investment opportunity.

Summary of DeFi Development Corp. (NasdaqCM:DFDV) Monthly Business Recap - February 5, 2026 Company Overview - **Company**: DeFi Development Corp. (DFDV) - **Industry**: Decentralized Finance (DeFi) Key Highlights Financial Performance - **Balance Sheet**: Approximately 2.2 million SOL held - **SPS (Stock Price)**: 0.0743 - **DFDV SOL Supply**: Over 512,000 SOL - **Trading Volume**: DFDVX (tokenized equity) recorded over $30 million in trading volume [5][6] Partnerships and Integrations - Expanded on-chain yield and treasury infrastructure through new integrations with HILO, Mooncake, Solstice, Yield Vault, and Jupiter Lend [5][6] Governance and Leadership - Added Hadley Stern, former Chief Commercial Officer at Marinade Finance, to the DFDV board [6][44] - Established a new revolving credit facility with DFDV UK [6] Market Conditions and Strategy - Current market conditions are volatile, with Bitcoin experiencing significant price drops, indicating a potential bear market [8][12] - The company is focused on long-term growth and development, emphasizing the importance of building during bear markets [19][20][22] Capital Allocation and Buybacks - The company is exploring preferred stock issuance but faces challenges due to current market conditions [39][40] - Engaged in share buybacks to grow SOL per share for long-term holders, with a focus on sustainable growth [41][42][43] Regulatory Environment - DFDV UK is navigating a more stringent regulatory environment compared to the U.S., which may slow down progress but is seen as a long-term opportunity [48][49] Experimentation with New Products - Launched a meme coin as an experiment to engage with the DeFi community and explore new avenues for growth and incentives [63][64][66] Additional Insights - The company acknowledges the current skepticism in the market but remains committed to its long-term vision and operational strategies [68] - Emphasizes the importance of building a robust foundation during market downturns, which historically leads to successful projects in subsequent bull markets [19][20] Conclusion - DeFi Development Corp. is actively navigating a challenging market environment while focusing on strategic growth, partnerships, and innovative product offerings. The leadership remains optimistic about the future and is committed to building a sustainable business model in the DeFi space.

NewLake Capital Partners (OTCPK:NLCP) Update / briefing February 05, 2026 02:00 PM ET Company ParticipantsAnthony Coniglio - President and CEOPablo Zuanic - Managing PartnerPablo ZuanicGood afternoon, everybody. It's Pablo Zuanic, Equity Analyst at Zuanic & Associates. I have the pleasure of introducing the CEO of NewLake Capital Partners, the sale-leaseback operator, Anthony Coniglio. Anthony, welcome.Anthony ConiglioHi, Pablo. How are you?Pablo ZuanicDoing fine, doing fine. Look, I mean, we're all waiting ...